Affibody vs Amyloid
Swedish and British researchers have shown that Affibody AB's Affibodies can be engineered to bind and clear toxic b-amyloid from the brains of fruit flies.1 The academics are now planning to look at the Affibodies in rodent models of Alzheimer's disease.
The biotech is helping by increasing the bioavailability of its lead Affibody for AD, ZAb3, but its focus remains on Affibodies for cancer.
High levels of b-amyloid (Ab) peptide in the brain, from either overproduction of the peptide or failure to clear it, are thought to lead to widespread Ab aggregates and plaques. These in turn cause neuronal and synaptic dysfunction and, ultimately, learning and memory deficits.
Because excessive Ab sits at the top of the amyloid cascade, one strategy has been to